{
    "clinical_study": {
        "@rank": "102612", 
        "acronym": "ABIDO", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "docetaxel 75 mg/m2 plus prednisone 10 mg/d combined with abiraterone acetate 1000 mg/d in 21 day cycles."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "Prostate cancer is the most frequently diagnosed non-skin cancer, and the second leading\n      cause of men cancer death in the United States. Hormonal therapy remains a first-line\n      treatment for metastatic prostate cancer. Initial responses to hormonal therapy with\n      chemical or surgical castration are quite favorable, however, most patients will progress to\n      a castration-resistant phase of the disease. Docetaxel is the primary chemotherapeutic\n      option for patients with mCRPC.\n\n      Abiraterone is a novel, selective, irreversible, and potent inhibitor of\n      17-[alpha]-hydroxylase/17,20-lyase (CYP17) enzymatic activity that has recently been\n      demonstrated to further reduce testosterone levels in the blood to undetectable range (< 1\n      ng/dL) and is suggested to reduce de novo intratumor androgen synthesis. Abiraterone\n      demonstrated activity in castration resistant prostate cancer patients previously treated\n      with docetaxel chemotherapy. Recently, results of a phase III trial comparing abiraterone\n      plus prednisone vs placebo plus prednisone in asymptomatic and without visceral metastasis,\n      castration-resistant metastatic prostate cancer patients, demonstrated a better radiological\n      progression free survival for abiraterone treated patients and a trend towards a better\n      survival was clear for abiraterone treated patients.\n\n      No clinical evidence exists about efficacy of chemotherapy and antiandrogen therapy\n      combination. All trials have been performed in patients in which LHRH agonist treatment was\n      continued although there is not clear evidence about efficacy of hormonal treatment. Some\n      retrospective studies suggest that androgen deprivation treatment should be maintained in\n      chemotherapy treated patients. Abiraterone has been proved to suppress androgen levels to\n      negative values, and to add efficacy to castration hormonal therapy. Combination of\n      abiraterone with docetaxel chemotherapy seems promising adding efficacy to only docetaxel\n      chemotherapy. A randomized phase II study comparing docetaxel + prednisone + abiraterone to\n      docetaxel + prednisone in mCRPC in patients treated previously with abiraterone, seems\n      promising to explore addition of efficacy to taxotere after abiraterone hormonal treatment."
        }, 
        "brief_title": "Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Prostate Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Disease Progression"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent\n\n          -  Male aged 18 years and above\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.\n\n          -  Metastatic disease documented by positive bone scan or metastatic lesions other than\n             liver or visceral metastasis on CT, MRI.\n\n          -  Prostate cancer progression to previous castration treatment documented by PSA\n             according to PCWG2 or radiographic progression according to modified RECIST criteria\n             or bone scan progression\n\n          -  Asymptomatic or mildly symptomatic from prostate cancer\n\n          -  Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM).\n\n          -  Previous anti-androgen therapy and progression after withdrawal.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Hemoglobin >= 10.0 g/dL independent of transfusion\n\n          -  Platelet count >= 100,000/\u00b5L\n\n          -  Serum albumin >= 3.5 g/dL\n\n          -  Serum creatinine < 1.5 x ULN or a calculated creatinine clearance >= 60 mL/min\n\n          -  Serum potassium >= 3.5 mmol/L\n\n          -  Liver function: a. Serum bilirubin < 1.5 x ULN (except for patients with documented\n             Gilbert's disease) b. AST or ALT < 2.5 x ULN\n\n          -  Life expectancy of at least 6 months\n\n          -  Patients who have partners of childbearing potential must be willing to use a method\n             of birth control\n\n        Exclusion Criteria:\n\n          -  Active infection or other medical condition that would make prednisone/prednisolone\n             (corticosteroid) use contraindicated\n\n          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10mg\n             prednisone/prednisolone daily.\n\n          -  Pathological finding consistent with small cell carcinoma of the prostate\n\n          -  Liver or visceral organ metastasis\n\n          -  Known brain metastasis\n\n          -  Use of opiate analgesics for cancer-related pain, including codeine and\n             dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1\n\n          -  Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC\n\n          -  Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day\n\n          -  Radiation or radionuclide therapy for treatment of metastatic CRPC\n\n          -  Previously treated with ketoconazole for prostate cancer for greater than 7 days\n\n          -  Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4\n             weeks of Cycle 1, Day 1\n\n          -  Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1\n\n          -  Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1\n\n          -  Uncontrolled hypertension (systolic BP >= 160 mmHg or diastolic BP >= 95 mmHg).\n\n          -  Active or symptomatic viral hepatitis or chronic liver disease\n\n          -  History of pituitary or adrenal dysfunction\n\n          -  Clinically significant heart disease\n\n          -  Atrial Fibrillation, or other cardiac arrhythmia requiring therapy\n\n          -  Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of\n             recurrence within 24 months\n\n          -  Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1\n\n          -  Any condition which, in the opinion of the investigator, would preclude participation\n             in this trial."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "119", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036060", 
            "org_study_id": "2013-003811-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Docetaxel 75 mg/m2 plus prednisone 10 mg/d combined with abiraterone acetate 1000 mg/d in 21 day cycles.", 
                "intervention_name": "Docetaxel, prednisone, abiraterone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.", 
                "intervention_name": "Docetaxel, prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisone", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic prostate cancer", 
            "Abiraterone acetate"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "eestebang@seom.org", 
                    "last_name": "Emilio Esteban, MD", 
                    "phone": "+34 985106121"
                }, 
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Universitario Central de Asturias"
                }, 
                "investigator": {
                    "last_name": "Emilio Esteban, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "afont@iconcologia.net", 
                    "last_name": "Albert Font, MD", 
                    "phone": "+34 934978925"
                }, 
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08916"
                    }, 
                    "name": "Hospital Universitari Germans Trias I Pujol"
                }, 
                "investigator": {
                    "last_name": "Albert Font, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "asanchezh@seom.org", 
                    "last_name": "Alfredo S\u00e1nchez, MD", 
                    "phone": "+34 964354355"
                }, 
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n de la Plana", 
                        "country": "Spain", 
                        "state": "Castell\u00f3n", 
                        "zip": "12002"
                    }, 
                    "name": "Consorcio Hospitalario Provincial de Castell\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Alfredo S\u00e1nchez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aranzazu.gonzalezdelalba@ssib.es", 
                    "last_name": "Aranzazu Gonz\u00e1lez del Alba, MD", 
                    "phone": "+34 871206130"
                }, 
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "state": "Islas Baleares", 
                        "zip": "07120"
                    }, 
                    "name": "Hospital Universitari Son Espases"
                }, 
                "investigator": {
                    "last_name": "Aranzazu Gonz\u00e1lez del Alba, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "martin.lazaro.quintela@sergas.es", 
                    "last_name": "Mart\u00edn L\u00e1zaro, MD", 
                    "phone": "+34 609110419"
                }, 
                "facility": {
                    "address": {
                        "city": "Vigo", 
                        "country": "Spain", 
                        "state": "Pontevedra", 
                        "zip": "36036"
                    }, 
                    "name": "Complexo Hospitalario Universitario de Vigo"
                }, 
                "investigator": {
                    "last_name": "Mart\u00edn L\u00e1zaro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmaroto@santpau.es", 
                    "last_name": "Pablo Maroto, Md", 
                    "phone": "+34 935565638"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de La Santa Creu I Sant Pau"
                }, 
                "investigator": {
                    "last_name": "Pablo Maroto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bmellado@clinic.ub.es", 
                    "last_name": "Bego\u00f1a Mellado, MD", 
                    "phone": "+34 932275402"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic I Provincial de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Bego\u00f1a Mellado, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mjosemv@yahoo.es", 
                    "last_name": "Mar\u00eda J M\u00e9ndez, MD", 
                    "phone": "+34 957011448"
                }, 
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }, 
                    "name": "Complejo Hospitalario Regional Reina Sof\u00eda"
                }, 
                "investigator": {
                    "last_name": "Mar\u00eda J M\u00e9ndez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jacaes@sescam.jccm.es", 
                    "last_name": "Javier Cassinello, MD", 
                    "phone": "+34 949209200"
                }, 
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Spain", 
                        "zip": "19002"
                    }, 
                    "name": "Hospital Universitario de Guadalajara"
                }, 
                "investigator": {
                    "last_name": "Javier Cassinello, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cdanicas@hotmail.com", 
                    "last_name": "Daniel E Castellano, Md", 
                    "phone": "+34 914692313"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Daniel E Castellano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "egrande@oncologiahrc.com", 
                    "last_name": "Enrique Grande, MD", 
                    "phone": "+34 913368263"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Ram\u00f3n Y Cajal"
                }, 
                "investigator": {
                    "last_name": "Enrique Grande, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jpuente.hcsc@salud.madrid.org", 
                    "last_name": "Javier Puente, MD", 
                    "phone": "+34 9133030007545"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Cl\u00ednico San Carlos"
                }, 
                "investigator": {
                    "last_name": "Javier Puente, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jarranza.oncomed@gmail.com", 
                    "last_name": "Jos\u00e9 A Arranz, MD", 
                    "phone": "+34 915868115"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 A Arranz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "msaez.med@gmail.com", 
                    "last_name": "Mar\u00eda I S\u00e1ez, MD", 
                    "phone": "+34 951032063"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }, 
                    "name": "Hospital Virgen de La Victoria"
                }, 
                "investigator": {
                    "last_name": "Mar\u00eda I S\u00e1ez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ignacio.duran.sspa@juntadeandalucia.es", 
                    "last_name": "Ignacio Dur\u00e1n, MD", 
                    "phone": "+34 955013068"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Complejo Hospitalario Regional Virgen Del Rocio"
                }, 
                "investigator": {
                    "last_name": "Ignacio Dur\u00e1n, Md", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "macliment@fivo.org", 
                    "last_name": "Miguel A Climent, MD", 
                    "phone": "+34 961114050"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46009"
                    }, 
                    "name": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda"
                }, 
                "investigator": {
                    "last_name": "Miguel A Climent, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "csantlob@yahoo.es", 
                    "last_name": "Carmen Santander, MD", 
                    "phone": "+34 976765500", 
                    "phone_ext": "3825"
                }, 
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Universitario Miguel Servet"
                }, 
                "investigator": {
                    "last_name": "Carmen Santander, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.", 
        "overall_contact": {
            "email": "macliment@fivo.org", 
            "last_name": "Miguel A Climent, MD", 
            "phone": "+34961114050"
        }, 
        "overall_contact_backup": {
            "email": "juanluis.sanz@apices.es", 
            "last_name": "Juan L Sanz", 
            "phone": "+34918166804", 
            "phone_ext": "103"
        }, 
        "overall_official": [
            {
                "affiliation": "FUNDACI\u00d3N INSTITUTO VALENCIANO DE ONCOLOG\u00cdA", 
                "last_name": "Miguel A Climent, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Jos\u00e9 A Arranz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARIO 12 DE OCTUBRE,Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Daniel E Castellano, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL CLINIC I PROVINCIAL DE BARCELONA, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Bego\u00f1a Mellado, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Albert Font, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELL\u00d3N, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Alfredo S\u00e1nchez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Emilio Esteban, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL VIRGEN DE LA VICTORIA, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Mar\u00eda I S\u00e1ez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARIO MIGUEL SERVET, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Carmen Santander, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL DE LA SANTA CREU I SANT PAU, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Pablo Maroto, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARI SON ESPASES, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Aranzazu Gonz\u00e1lez del Alba, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL RAM\u00d3N Y CAJAL, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Enrique Grande, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL CL\u00cdNICO SAN CARLOS, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Javier Puente, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "COMPLEXO HOSPITALARIO UNIVERSITARIO DE VIGO, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Mart\u00edn L\u00e1zaro, Md", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HOSPITAL UNIVERSITARIO DE GUADALAJARA, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Javier Cassinello, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "COMPLEJO HOSPITALARIO REGIONAL REINA SOF\u00cdA,  Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Mar\u00eda J M\u00e9ndez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "COMPLEJO HOSPITALARIO REGIONAL VIRGEN DEL ROCIO, Servicio de Oncolog\u00eda M\u00e9dica", 
                "last_name": "Ignacio Dur\u00e1n, Md", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time from randomization to radiologic disease progression", 
            "measure": "1 year radiologic progression free survival", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036060"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from randomization to death", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Time from randomization to radiologic progression free survival", 
                "measure": "Radiologic progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Time from randomization to PSA progression", 
                "measure": "PSA progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 weeks"
            }, 
            {
                "description": "50% & 90% PSA reduction from randomisation", 
                "measure": "PSA response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 weeks"
            }, 
            {
                "description": "Response according RECIST criteria", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Quality of life according to FACT-P questionaire", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Time from randomization to skeletal-related events", 
                "measure": "Time to skeletal-related event", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Time from randomization to opiate use for cancer pain", 
                "measure": "Time to opiate use for cancer pain", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 weeks"
            }, 
            {
                "description": "Time from randomization to pain progression defined as an increase in median BPI score \u2265 30% from baseline", 
                "measure": "Time to pain progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 weeks"
            }, 
            {
                "description": "Related adverse events per patient", 
                "measure": "Safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 weeks"
            }
        ], 
        "source": "Spanish Oncology Genito-Urinary Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spanish Oncology Genito-Urinary Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}